

MARKET RELEASE

Results of 2020 Annual General Meeting

Melbourne, Australia, 21 December, 2020 – Medtech company MedAdvisor Limited (ASX: MDR) is pleased to advise that all resolutions proposed at today's annual general meeting were passed on a poll by the requisite majorities.

In accordance with the Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, details of the poll voting results and proxy votes for the resolutions are attached.

This document has been authorised for release by Naomi Lawrie, MedAdvisor Company Secretary.

- ENDS -

For more information:

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Alex Beashel
Corporate Communications
ab@alexbeashel.com
+61 466 308 667

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors

MEDADVISOR LIMITED ACN 145 327 617
RESULTS OF ANNUAL GENERAL MEETING

Monday, 21 December 2020

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details			Instructions given to validly appointed proxies (as at proxy close)				Number of votes casts on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	Strike Y/N /NA	For	Against	Proxy's Discretion	Abstain*	For	Against	Abstain*	Carried / Not Carried
1. Adoption of Remuneration Report	Ordinary	N	126,237,228 98.07%	1,617,663 1.26%	857,104 0.67%	17,120	127,113,332 98.74%	1,617,663 1.26%	117,120	Carried
2. Re-election of Director – Mr Josh Swinnerton	Ordinary	N/A	170,854,524 98.94%	935,262 0.54%	898,303 0.52%	416,675	171,771,827 99.46%	935,262 0.54%	516,675	Carried
3. Re-election of Director – Mr Jim Xenos	Ordinary	N/A	148,161,959 90.82%	14,085,157 8.63%	900,803 0.55%	9,956,845	149,081,762 91.37%	14,085,157 8.63%	10,056,845	Carried
4. Re-election of Director – Mr Christopher Ridd	Ordinary	N/A	170,244,332 98.35%	1,954,976 1.13%	898,303 0.52%	7,153	171,261,635 98.97%	1,954,976 1.13%	7,153	Carried
5. Approval of 10% Placement Capacity	Special	N/A	154,542,078 91.38%	13,661,024 8.08%	917,104 0.54%	3,984,558	155,478,182 91.92%	13,661,024 8.08%	4,084,558	Carried
6. Ratification of Prior Placement under Listing Rule 7.1	Ordinary	N/A	145,154,826 90.31%	13,699,587 8.52%	1,895,818 1.17%	12,249,270	147,069,644 91.48%	13,699,587 8.52%	12,349,270	Carried
7. Approval of Issue of Convertible Note to Syneos Health	Ordinary	N/A	168,873,686 99.31%	299,989 0.18%	871,304 0.51%	3,059,785	169,863,990 99.82%	299,989 0.18%	3,059,785	Carried
8. Issue of Employee Incentive Options to Mr Robert Read, CEO and Managing Director	Ordinary	N/A	167,544,972 98.42%	1,821,250 1.07%	867,104 0.51%	2,871,438	168,521,076 98.93%	1,821,250 1.07%	2,881,438	Carried
9. Issue of Options to Mr Christopher Ridd	Ordinary	N/A	143,662,435 83.00%	28,567,105 16.50%	867,104 0.50%	8,120	144,648,539 83.51%	28,567,105 16.49%	8,120	Carried
10. Placement of Shares to Mr Christopher Ridd	Ordinary	N/A	169,439,576 97.89%	2,789,964 1.61%	867,104 0.50%	8,120	170,325,680 98.39%	2,789,964 1.61%	8,120	Carried

* Votes cast by a person who abstains on an item are not counted in counting the required majority on a poll.